NASDAQ:KALA • US4831192020
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for KALA BIO INC (KALA).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-09-29 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-09-17 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-09-11 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-09-08 | Mizuho | Initiate | Outperform |
| 2025-05-23 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-04-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-19 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-05-17 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-04-02 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-04-01 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2023-11-17 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-08-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-10 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-05-01 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-04-12 | HC Wainwright & Co. | Maintains | Buy |
| 2023-03-27 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-06 | HC Wainwright & Co. | Maintains | Buy |
| 2022-08-15 | HC Wainwright & Co. | Maintains | Buy |
| 2022-05-24 | HC Wainwright & Co. | Maintains | Buy |
| 2022-05-17 | HC Wainwright & Co. | Maintains | Buy |
| 2021-08-06 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2021-08-06 | HC Wainwright & Co. | Maintains | Buy |
| 2021-05-06 | HC Wainwright & Co. | Maintains | Buy |
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 6.36M 4.78% | 11.24M 76.73% | 3.89M -65.39% | -100.00% | 129.44M | 199.41M 54.06% | ||||||||
| EBITDA YoY % growth | -95.32M -9.09% | -129.27M -35.62% | -81.16M 37.22% | N/A 51.50% | N/A -3.51% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -96.23M -9.08% | -130.25M -35.35% | -81.7M 37.27% | -41.17M 51.45% | -42.456M -3.37% | -41.392M -0.96% | -8.395M 79.72% | -8.804M -4.87% | -8.979M -1.99% | -9.159M -2.00% | -9.342M -2.00% | 61.302M 756.19% | 115.87M 89.02% | |
| Operating Margin | -1,513.05% | -1,158.81% | -2,100.26% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 47.36% | 58.11% | |
| EPS YoY % growth | -100.50 27.17% | -108.50 -7.96% | -30.22 72.15% | -18.39 40.64% | -11.05 38.57% | -5.55 49.59% | -0.90 83.77% | -0.41 54.75% | N/A | N/A | N/A | N/A | N/A |
All data in USD
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.90 48.47% | -0.24 82.86% | -0.21 87.65% | -0.23 73.20% | -0.22 75.65% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -7.47M 21.03% | -2.46M 76.94% | -2.028M 81.61% | -1.978M 66.06% | -1.93M 74.17% |
All data in USD
7 analysts have analysed KALA and the average price target is 1.53 USD. This implies a price increase of 450.16% is expected in the next year compared to the current price of 0.2781.
KALA BIO INC (KALA) will report earnings on 2026-03-30, after the market close.
The consensus EPS estimate for the next earnings of KALA BIO INC (KALA) is -0.9 USD and the consensus revenue estimate is 0 USD.
The number of analysts covering KALA BIO INC (KALA) is 7.